IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
DOI:
https://doi.org/10.2340/1651-226X.2024.28322Keywords:
Advanced cancer, targeted therapies, precision cancer medicine, drug repurposing, IMPRESS-NorwayAbstract
Background and purpose: In Norway, comprehensive molecular tumour profiling is implemented as part of the public healthcare system. A substantial number of tumours harbour potentially targetable molecular alterations. Therapy outcomes may improve if targeted treatments are matched with actionable genomic alterations. In the IMPRESS-Norway trial (NCT04817956), patients are treated with drugs outside the labelled indication based on their tumours molecular profile.
Patients and methods: IMPRESS-Norway is a national, prospective, non-randomised, precision cancer medicine trial, offering treatment to patients with advanced-stage disease, progressing on standard treatment. Comprehensive next-generation sequencing, TruSight Oncology 500, is used for screening. Patients with tumours harbouring molecular alterations with matched targeted therapies available in IMPRESS-Norway, are offered treatment. Currently, 24 drugs are available in the study. Primary study endpoints are percentage of patients offered treatment in the trial, and disease control rate (DCR) defined as complete or partial response or stable disease in evaluable patients at 16 weeks (W16) of treatment. Secondary endpoint presented is DCR in all treated patients.
Results: Between April 2021 and October 2023, 1,167 patients were screened, and an actionable mutation with matching drug was identified for 358 patients. By the data cut off 186 patients have initiated treatment, 170 had a minimum follow-up time of 16 weeks, and 145 also had evaluable disease. In patients with evaluable disease, the DCR was 40% (58/145). Secondary endpoint analysis of DCR in all treated patients, showed DCR of 34% (58/170).
Interpretation: Precision cancer medicine demonstrates encouraging clinical effect in a subset of patients included in the IMPRESS-Norway trial.
Downloads
References
Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, Enerly E, et al. A national precision can-cer medicine implementation initiative for Norway. Nat Med. 2022;28(5):885–887.
https://doi.org/10.1038/s41591-022-01777-4 DOI: https://doi.org/10.1038/s41591-022-01777-4
van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkho-ven E, Roepman P, et al. The drug rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574(7776):127–131.
https://doi.org/10.1038/s41586-019-1600-x DOI: https://doi.org/10.1038/s41586-019-1600-x
Kringelbach T, Højgaard M, Rohrberg K, Spanggaard I, Laursen BE, Ladekarl M, et al. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. BMC Cancer. 2023;23(1):182.
https://doi.org/10.1186/s12885-023-10632-9 DOI: https://doi.org/10.1186/s12885-023-10632-9
ClinicalTrials.gov.org [Internet]. The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE). [updated 2023 Sep 22; cited 2024 Feb 22]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05159245.
Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, et al. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. J Transl Med. 2022;20(1):225.
https://doi.org/10.1186/s12967-022-03432-5 DOI: https://doi.org/10.1186/s12967-022-03432-5
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10.
https://doi.org/10.1016/0197-2456(89)90015-9 DOI: https://doi.org/10.1016/0197-2456(89)90015-9
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New re-sponse evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
https://doi.org/10.1016/j.ejca.2008.10.026 DOI: https://doi.org/10.1016/j.ejca.2008.10.026
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Upda-ted response assessment criteria for high-grade gliomas: response assess-ment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–1972.
https://doi.org/10.1200/JCO.2009.26.3541 DOI: https://doi.org/10.1200/JCO.2009.26.3541
Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and Euro-pean LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395–1398.
https://doi.org/10.1182/blood-2013-03-488098 DOI: https://doi.org/10.1182/blood-2013-03-488098
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. Internat-ional Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
https://doi.org/10.1016/S1470-2045(14)70442-5 DOI: https://doi.org/10.1016/S1470-2045(14)70442-5
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TAet al. Re-commendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
https://doi.org/10.1200/JCO.2013.54.8800 DOI: https://doi.org/10.1200/JCO.2013.54.8800
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guide-lines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e152.
https://doi.org/10.1016/S1470-2045(17)30074-8 DOI: https://doi.org/10.1016/S1470-2045(17)30074-8
Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, et al. Impact of a bi-omarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J Natl Cancer Inst. 2015;107(11):djv253.
https://doi.org/10.1093/jnci/djv253 DOI: https://doi.org/10.1093/jnci/djv253
Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hüllein J, et al. Comprehensive ge-nomic and transcriptomic analysis for guiding therapeutic decisions in pa-tients with rare cancers. Cancer Discov. 2021;11(11):2780–2795.
https://doi.org/10.1158/2159-8290.CD-21-0126 DOI: https://doi.org/10.1158/2159-8290.CD-21-0126
Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol. 2015;33(25):2753–2762.
https://doi.org/10.1200/JCO.2014.60.4165 DOI: https://doi.org/10.1200/JCO.2014.60.4165
Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–1334.
https://doi.org/10.1016/S1470-2045(15)00188-6 DOI: https://doi.org/10.1016/S1470-2045(15)00188-6
Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced can-cers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586–595.
https://doi.org/10.1158/2159-8290.CD-16-1396 DOI: https://doi.org/10.1158/2159-8290.CD-16-1396
Tuxen IV, Rohrberg KS, Oestrup O, Ahlborn LB, Schmidt AY, Spanggaard I, et al. Copenha-gen Prospective Personalized Oncology (CoPPO)-clinical utility of using mo-lecular profiling to select patients to Phase I trials. Clin Cancer Res. 2019;25(4):1239–1247.
https://doi.org/10.1158/1078-0432.CCR-18-1780 DOI: https://doi.org/10.1158/1078-0432.CCR-18-1780
Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, et al. Tar-geted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, Phase IIa multiple basket study. J Clin Oncol. 2018;36(6):536–542.
https://doi.org/10.1200/JCO.2017.75.3780 DOI: https://doi.org/10.1200/JCO.2017.75.3780
MATRIX – Clinical Research Center [Internet]. PCM4EU – Personalized cancer medicine for all EU citizens. [updated 2024 Jan; cited 2024 Feb 22]. Available from: https://www.matrix-fkb.no/en/pcm4eu/home
MATRIX – Clinical Research Center [Internet]. PRIME-ROSE – Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials. [updated 2024 Jan; cited 2022 Jan 22]. Available from: https://www.matrix-fkb.no/en/prime-rose/home
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Katarina Puco, Gro Live Fagereng, Sigmund Brabrand, Pitt Niehusmann, Egil Støre Blix, Eli Sihn Samdal Steinskog, Åse Haug, Cecilie Fredvik Torkildsen, Irja Alida Oppedal, Sebastian Meltzer, Åsmund Flobak, Kajsa Anna Margareta Johansson, Line Bjørge, Geir Olav Hjortland, Astrid Dalhaug, Jo-Åsmund Lund, Bjørnar Gilje, Marte Grønlie Cameron, Randi Hovland, Ragnhild S. Falk, Sigbjørn Smeland, Hege Elisabeth Giercksky Russnes, Kjetil Taskén, Åslaug Helland
This work is licensed under a Creative Commons Attribution 4.0 International License.
